We are live on !
Find out more
Deerfield Management Portfolio holdings
AUM
$9.6B
Turnover
24.47%
1-Year Est. Return
113.36%
This Fund
S&P 500
This Quarter Est. Return
+17.58%
1 Year Est. Return
+113.36%
3 Year Est. Return
+277.48%
5 Year Est. Return
+350.78%
10 Year Est. Return
+2,290.11%
AUM
$9.6B
AUM Growth
+$1.11B
(+13%)
Cap. Flow
-$1.32B
Cap. Flow % of AUM
Cap. Flow %
-13.72%
Top 10 Holdings %
Top 10 Hldgs %
53.17%
Holding
94
New
11
Increased
13
Reduced
11
Closed
12
Avg Time Held
1.9
years
Top 10 Avg Time Held
1.1
years
Top 20 Avg Time Held
1.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Genmab
GMAB
|
+$117M |
| 2 |
Mineralys Therapeutics
MLYS
|
+$109M |
| 3 |
Boston Scientific
BSX
|
+$71.4M |
| 4 |
PBLS
Parabilis Medicines Inc
PBLS
|
+$52M |
| 5 |
IDEAYA Biosciences
IDYA
|
+$36.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cogent Biosciences
COGT
|
+$141M |
| 2 |
Catalyst Pharmaceutical
CPRX
|
+$97.6M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$80.4M |
| 4 |
Day One Biopharmaceuticals
DAWN
|
+$79.8M |
| 5 |
Enhabit
EHAB
|
+$66.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.76% |
| 2 | Miscellaneous | 16.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
DELISTED
Nuvalent
NUVL
| $2.13B | 22.22% |
17,248,450
| – | – |
2021 Q3
19 quarters
|
|
2
Revolution Medicines
RVMD
$39.4B
| $448M | 4.67% |
2,392,000
+95,000
| +4% | +$13.9M |
2020 Q1
25 quarters
|
|
3
Praxis Precision Medicines
PRAX
$6.93B
| $323M | 3.36% |
963,351
| – | – |
2025 Q1
5 quarters
|
|
4
Viatris
VTRS
$21.3B
| $321M | 3.35% |
20,206,170
| – | – |
2015 Q1
45 quarters
|
|
5
Centene
CNC
$34.1B
| $315M | 3.28% |
4,901,000
-1,016,091
| -17% | -$54.3M |
2018 Q1
33 quarters
|
|
6
United Therapeutics
UTHR
$23.1B
| $248M | 2.58% |
457,000
| – | – |
2025 Q1
5 quarters
|
|
7
Legend Biotech
LEGN
$3.64B
| $235M | 2.45% |
8,137,638
+450,000
| +6% | +$12.1M |
2024 Q4
6 quarters
|
|
|
8
Cogent Biosciences
COGT
$5.21B
| $194M | 2.02% |
5,006,104
-4,037,799
| -45% | -$141M |
2020 Q4
22 quarters
|
|
|
9
Genmab
GMAB
$23.7B
| $189M | 1.97% |
6,865,000
+4,403,000
| +179% | +$117M |
2026 Q1
1 quarter
|
|
10
Brookdale Senior Living
BKD
$2.4B
| $187M | 1.95% |
11,637,032
| – | – |
2018 Q2
32 quarters
|
|
11
Vera Therapeutics
VERA
$2.03B
| $168M | 1.75% |
3,916,400
+194,300
| +5% | +$7.24M |
2025 Q1
5 quarters
|
|
12
Ionis Pharmaceuticals
IONS
$7.25B
| $157M | 1.64% |
1,979,669
| – | – |
2025 Q3
3 quarters
|
|
13
Celcuity
CELC
$2.83B
| $152M | 1.58% |
1,451,014
-262,986
| -15% | -$30.3M |
2025 Q3
3 quarters
|
|
14
BioCryst Pharmaceuticals
BCRX
$2.03B
| $151M | 1.57% |
15,096,403
+58,403
| +0.4% | +$528K |
2023 Q1
13 quarters
|
|
15
NewAmsterdam Pharma
NAMS
$2.42B
| $145M | 1.51% |
4,264,789
| – | – |
2024 Q1
9 quarters
|
|
16
Acadia Healthcare
ACHC
$2.84B
| $133M | 1.39% |
4,520,000
| – | – |
2025 Q3
3 quarters
|
|
17
Tango Therapeutics
TNGX
$3.91B
| $131M | 1.37% |
4,190,611
+43,798
| +1% | +$1.08M |
2025 Q4
2 quarters
|
|
18
AdaptHealth
AHCO
$790M
| $120M | 1.25% |
11,477,730
| – | – |
2019 Q4
26 quarters
|
|
19
Pharvaris
PHVS
$2.02B
| $117M | 1.22% |
3,376,042
+250,000
| +8% | +$7.56M |
2023 Q4
10 quarters
|
|
20
Arrowhead Research
ARWR
$8.06B
| $113M | 1.18% |
1,389,055
-184,242
| -12% | -$13.6M |
2025 Q3
3 quarters
|
|
21
Dianthus Therapeutics
DNTH
$4.15B
| $110M | 1.14% |
1,125,313
+105,500
| +10% | +$9.21M |
2026 Q1
1 quarter
|
|
22
Larimar Therapeutics
LRMR
$210M
| $109M | 1.13% |
35,606,974
| – | – |
2020 Q2
24 quarters
|
|
|
23
Mineralys Therapeutics
MLYS
$1.85B
| $107M | 1.11% |
+3,958,000
| New | +$109M |
2026 Q2
0 quarters
|
|
|
24
IDEAYA Biosciences
IDYA
$3.23B
| $101M | 1.06% |
2,714,503
+1,184,495
| +77% | +$36.3M |
2022 Q3
15 quarters
|
|
25
Xenon Pharmaceuticals
XENE
$3.31B
| $97.5M | 1.02% |
1,615,696
| – | – |
2025 Q2
4 quarters
|
|
Similar funds
GGHC
SC
Deerfield Management's Q2 2026 Portfolio in Review
As of Q2 2026, Deerfield Management held 94 positions worth $9.6B, up 13% from $8.48B the previous quarter. Its ten largest holdings account for 53% of the portfolio.
Deerfield Management withdrew a net $1.32B in Q2 2026, closing 12 positions and reducing 11 holdings. Its most notable exit was Catalyst Pharmaceutical, an estimated $97.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 85% a quarter earlier, followed by Miscellaneous.
Against the trend, Deerfield Management opened a new position in Mineralys Therapeutics worth $107M.
- Deerfield Management's largest Q2 2026 buy was Mineralys Therapeutics: 3,958,000 shares worth $107M.
- Deerfield Management added most to Genmab in Q2 2026, an estimated $117M increase.
- Deerfield Management's biggest Q2 2026 reduction was Cogent Biosciences, cutting an estimated $141M.
- Deerfield Management fully exited Catalyst Pharmaceutical in Q2 2026, selling an estimated $97.6M.
- Deerfield Management's ten largest holdings make up 53% of its $9.6B portfolio in Q2 2026.
- Deerfield Management opened 11 new positions and closed 12 in Q2 2026.
- Deerfield Management's portfolio value rose 13% quarter-over-quarter to $9.6B.
Based on Deerfield Management's 13F filing for Q2 2026, filed 14 Aug 2026.